Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 3/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25564557 | 0.95 | FAP (0.38) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL21082516 | 0.92 | FAP (0.39) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL24095912 | 0.92 | FAP (0.40) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL26560488 | 0.90 | FAP (0.39) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22871647 | 0.88 | FAP (0.38) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL19869029 | 0.87 | FAP (0.40) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL25833839 | 0.86 | CYP3A4 (0.41) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL24668375 | 0.86 | FAP (0.45) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL24584968 | 0.85 | FAP (0.39) | FAPFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL20798881 | 0.85 | FAP (0.38) | FAPFURINSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | FAP 577/4885FURIN 826/4885SIRT2 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.